myelodysplastic-syndrome
18
Myelodysplastic Syndrome

Myelodysplastic Syndrome

Last Reviewed : 12/24/2020
Myelodysplastic Syndrome

The myelodysplastic syndromes (also known as MDS or myelodysplasia) are hematological (i.e., blood-related) medical conditions with ineffective production (or "dysplasia") of all blood cells.

Patients with MDS can develop severe anemia and require blood transfusions. In some cases, the disease worsens and the patient develops cytopenias (low blood counts) caused by progressive bone marrow failure. The outlook in MDS depends on the type and severity. Many people live normal lifespans with MDS.

The myelodysplastic syndromes are all disorders of the hematopoietic stem cells in the bone marrow (only related tomyeloid lineage). In MDS, hematopoiesis (i.e., blood production) is disorderly and ineffective. The number and quality of blood-forming cells decline irreversibly, further impairing blood production. The mean age of onset of MDS is 68 years.

We researched this topic for you and found the following best online resources. They are categorized into basic, advanced, and research level based on the extent of information you need. You will be taken to the respective websites by pressing on the links below.

 

Basic information:

http://www.webmd.com/cancer/tc/myelodysplastic-syndromes-treatment-patient-information-nci-pdq-general-information-about web md myelodysplastic syndromes

http://www.mayoclinic.org/diseases-conditions/myelodysplastic-syndromes/basics/definition/con-20027168 mayoclinic myelodysplastic syndromes

http://www.nhs.uk/conditions/myelodysplasia/pages/introduction.aspx nhs uk myelodysplastic syndromes

http://www.leukaemia.org.au/blood-cancers/myelodysplastic-syndrome-mds leukemia foundation myelodysplastic syndromes

http://www.merckmanuals.com/professional/hematology-and-oncology/leukemias/myelodysplastic-syndrome merck manuals(professional version) myelodysplastic syndromes

http://my.clevelandclinic.org/health/diseases_conditions/myelodysplastic-syndrome cleveland clinic myelodysplastic syndromes

 

Advanced information:

http://emedicine.medscape.com/article/207347-overview medscape myelodysplastic syndromes

http://www.cancer.net/cancer-types/myelodysplastic-syndromes-mds/treatment-options cancer.net myelodysplastic syndromes

http://patient.info/doctor/myelodysplastic-syndromes-pro patient myelodysplastic syndromes

https://www.nlm.nih.gov/medlineplus/myelodysplasticsyndromes.html medline plus myelodysplastic syndromes

https://labtestsonline.org/understanding/conditions/myelodysplastic-syndrome/start/1 lab teste online myelodysplastic syndromes

http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology-oncology/myelodysplastic-syndromes/ cleveland clinic myelodysplastic syndromes

http://www.uptodate.com/contents/myelodysplastic-syndromes-mds-in-adults-beyond-the-basics upto date patient information: myelodysplastic syndromes (mds) in adults (beyond the basics)

http://rarediseases.org/rare-diseases/myelodysplastic-syndromes/ national organisation of rare diseases myelodysplastic syndromes

http://www.esmo.org/guidelines/haematological-malignancies/myelodysplastic-syndromes myelodysplastic syndromes: esmo clinical practice guidelines published in 2014 – ann oncol (2014) 25 (suppl 3): iii57-iii69. authors: p. fenaux, d. haase, g. f. sanz, v. santini, c. buske

http://radiopaedia.org/articles/myelodysplastic-syndrome radiopedia myelodysplastic syndromes

 

Research:

http://www.hindawi.com/journals/ah/2010/164045/ maha a. badawi, linda m. vickars, jocelyn m. chase, and heather a. leitch, “red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome,” advances in hematology, vol. 2010, article id 164045, 5 pages, 2010. doi:10.1155/2010/164045

http://www.scielo.br/scielo.php?script=sci_arttext&pid=s1516-84842001000200002 rev. bras. hematol. hemoter. vol.23 no.2 são josé do rio preto may/aug. 2001 http://dx.doi.org/10.1590/s1516-84842001000200002 article:myelodysplastic syndromes: histopathology as prognostic factor by maura romeo et al.,

http://hqlo.biomedcentral.com/articles/10.1186/1477-7525-7-81 valuation of transfusion-free living in mds: results of health utility interviews with patients by agota szende et al., health and quality of life outcomes20097:81 doi: 10.1186/1477-7525-7-81

http://www.hindawi.com/journals/crionm/2016/8308179/ udit bhaskar bhatnagar, daulath singh, alexy glazyrin, and jill moormeier, “paclitaxel induced mds and aml: a case report and literature review,” case reports in oncological medicine, vol. 2016, article id 8308179, 5 pages, 2016. doi:10.1155/2016/8308179

http://europepmc.org/backend/ptpmcrender.fcgi?accid=pmc3157379&blobtype=pdf : qin t, castoro r, el ahdab s, jelinek j, wang x, et al. (2011) mechanisms of resistance to decitabine in the myelodysplastic syndrome. plos one 6(8):e23372. doi:10.1371/journal.pone.0023372

khodadad k, sadeghipour a, aghili n. generalized neutrophilic dermatosis: a rare presentation of myelodysplastic syndrome. indian j cancer [serial online] 2005 [cited 2016 jun 29];42:57-9. available from: http://www.indianjcancer.com/text.asp?2005/42/1/57/15102

http://www.scielo.br/scielo.php?script=sci_arttext&pid=s1516-84842014000300196&lng=en&tlng=en rev. bras. hematol. hemoter. vol.36 no.3 são josé do rio preto may/june 2014 http://dx.doi.org/10.1016/j.bjhh.2014.03.007 original articles:tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome by fernando barroso duarte et al.,

george n, santhosh vc, kumar h, gopal s. gingival enlargement in myelodysplastic syndrome. j indian soc periodontol [serial online] 2015 [cited 2016 jun 29];19:687-9. available from: http://www.jisponline.com/text.asp?2015/19/6/687/164761

http://europepmc.org/backend/ptpmcrender.fcgi?accid=pmc3350481&blobtype=pdf gough sm, chung yj, aplan pd (2012) depletion of cytotoxic t-cells does not protect nup98-hoxd13 mice from myelodysplastic syndrome but reveals a modest tumor immunosurveillance effect. plos one 7(5): e36876. doi:10.1371/journal.pone.0036876

http://www.mdpi.com/1422-0067/17/6/944/htm int. j. mol. sci. 2016, 17(6), 944; doi:10.3390/ijms17060944 review:immune mechanisms in myelodysplastic syndrome by andreas glenthøj et al.,

http://www.mdpi.com/1422-0067/16/1/966/htm int. j. mol. sci. 2015, 16(1), 966-989; doi:10.3390/ijms16010966 review : potential relationship between inadequate response to dna damage and development of myelodysplastic syndrome by ting zhou et al.,

 

Other helpful resources(support groups):

http://www.mds-foundation.org/what-is-mds/ mds foundation

 

Related videos:

https://www.youtube.com/watch?v=7j6hcztlldw myelodysplastic syndromes

https://www.youtube.com/watch?v=acifjgqgesw what is mds (myelodysplastic syndromes)?

https://www.youtube.com/watch?v=skrof6-z2hc the natural history of myelodysplastic syndromes (intermediate level)

https://www.youtube.com/watch?v=txbu_c8wnqs myelodysplastic syndrome causes and treatment

https://www.youtube.com/watch?v=3g8ngdyh0zc myelodysplastic syndrome | dr. tony talebi discusses myelodysplastic syndrome

https://www.youtube.com/watch?v=e1qfuitvquk 6th lecture myelodysplastic syndromes neoplasms

https://www.youtube.com/watch?v=djeaqvzaq2g what is new in treatment research for myelodysplastic syndrome?

 

Presentations/quiz/newspaper articles:

http://www.cbs8.com/story/32298892/global-myelodysplastic-syndrome-pipeline-report-2016-pipeline-review-of-92-therapeutic-companies-research-and-markets global myelodysplastic syndrome pipeline report 2016 - pipeline review of 92 therapeutic companies - research and markets

Please leave your comments:



Related Articles